The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | KEYNOTE-189: chemo plus pembrolizumab for NSCLC
The KEYNOTE-189 ( NCT02578680) trial investigated the effects of adding pembrolizumab to cisplatin and pemetrexed in patients with non-small cell lung cancer (NSCLC). Here, Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy, explains the methodology behind the trial and goes through the promising results that have been obtained to date, emphasizing how slight variations in pembrolizumab dosage can affect the overall efficacy of the treatment. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL.
